用MVA85A增强卡介苗：首个进入临床试验的结核亚单位候选疫苗。
Boosting BCG with MVA85A: the first candidate subunit vaccine for tuberculosis in clinical trials.
作者信息
McShane Helen, Pathan Ansar A, Sander Clare R, Goonetilleke Nilu P, Fletcher Helen A, Hill Adrian V S
机构信息
Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, Churchill Hospital, Oxford OX3 7LJ, UK.
出版信息
Tuberculosis (Edinb). 2005 Jan-Mar;85(1-2):47-52. doi: 10.1016/j.tube.2004.09.015. Epub 2005 Jan 21.
There is an urgent need for an improved vaccine against tuberculosis. Heterologous prime-boost immunization regimes induce higher levels of cellular immunity than homologous boosting with the same vaccine. Using BCG as the priming immunization in such a regime allows for the retention of the beneficial protective effects of BCG against disseminated disease in childhood. Recombinant poxviruses are powerful boosting agents, for both CD4+ and CD8+ T cells. Here we review the preclinical data from a BCG prime-recombinant modified vaccinia virus Ankara expressing antigen 85A (MVA85A) boost strategy. MVA85A is now in clinical trials in the UK and Africa and the design of these trials, including the ethical and regulatory issues are discussed.
迫切需要一种改进的抗结核疫苗。与使用相同疫苗进行同源加强免疫相比，异源初免 - 加强免疫方案可诱导更高水平的细胞免疫。在这样的方案中使用卡介苗作为初免接种可保留卡介苗对儿童播散性疾病的有益保护作用。重组痘病毒是针对CD4 +和CD8 + T细胞的强大加强免疫剂。在此，我们综述了卡介苗初免 - 重组表达85A抗原的安卡拉痘苗病毒（MVA85A）加强免疫策略的临床前数据。MVA85A目前正在英国和非洲进行临床试验，并讨论了这些试验的设计，包括伦理和监管问题。
Zotero 插件